Private Equity VC Fund Investments
Cell therapy player Eyestem raises $6.4 M from strategic investors, existing VCs
Eyestem, a Bengaluru-based cell therapy company, has raised USD 6.4 million (INR 51 crore) in a Series A round led by Biological E, Alkem, Natco and Anurag and Karan Bagaria, promoters of Kemwell Biopharma. Existing PE-VC investors Endiya Partners and Kotak Private Equity also participated in this round, which valued Eyestem at USD 46.4 million (INR 371 crore).
Eyecyte-RPE, the company's patented flagship product, is an experimental treatment for Dry Age-Related Macular Degeneration (Dry AMD) and the company has other products in the pipeline for the treatment of incurable diseases.
Company website ↗ (opens in a new tab)
From the Venture Intelligence PE-VC Deal Database: In May-2021, Eyestem had raised over INR 5 Cr from Endiya Partners and Kotak Investment Advisors. (Subscribers to the database can login to view the valuation, deal structuring and other transaction details.)